Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial.

Negrier S, Rioux-Leclercq N, Ferlay C, Gross-Goupil M, Gravis G, Geoffrois L, Chevreau C, Boyle H, Rolland F, Blanc E, Ravaud A, Dermeche S, Flechon A, Albiges L, Pérol D, Escudier B; GETUG collaborative group.

Eur J Cancer. 2020 Apr;129:107-116. doi: 10.1016/j.ejca.2020.02.001. Epub 2020 Mar 5.

PMID:
32146304
2.

Prognostic factors for cancer patient admitted to a medical intensive care unit.

Baylot C, Francopoulo A, Gross-Goupil M, Quivy A, Guisset O, Hilbert G, Frison E, Ravaud A, Daste A.

Acta Oncol. 2020 Apr;59(4):458-461. doi: 10.1080/0284186X.2019.1711171. Epub 2020 Jan 16. No abstract available.

PMID:
31948319
3.

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group.

Sroussi M, Elaidi R, Fléchon A, Lorcet M, Borchiellini D, Tardy MP, Gravis G, Guérin M, Laguerre B, Estrade F, Delva R, Barthélémy P, Loriot Y, Lavaud P, Lebret T, Neuzillet Y, Penel N, Houede N, Pouessel D, Rousseau B, Mussat E, Gross-Goupil M, Culine S, Gauthier H, Gobert A, Roupret M, Huillard O, Tartas S, Radulescu C, Allory Y, Oudard S.

Clin Genitourin Cancer. 2019 Dec 5. pii: S1558-7673(19)30365-9. doi: 10.1016/j.clgc.2019.11.014. [Epub ahead of print]

PMID:
31882335
4.

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience.

Gonnet A, Salabert L, Roubaud G, Catena V, Brouste V, Buy X, Gross Goupil M, Ravaud A, Palussière J.

BMC Cancer. 2019 Dec 3;19(1):1182. doi: 10.1186/s12885-019-6345-2.

5.

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier E, Deville JL, Gross-Goupil M, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthélémy P, Sella A, Fizazi K, Ferrero JM, Laguerre B, Thibault C, Hans S, Oudard S.

Eur J Cancer. 2020 Jan;125:153-163. doi: 10.1016/j.ejca.2019.10.030. Epub 2019 Nov 29.

PMID:
31787484
6.

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.

Antonarakis ES, Piulats JM, Gross-Goupil M, Goh J, Ojamaa K, Hoimes CJ, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata KI, Park SH, Feyerabend S, Drake CG, Wu H, Qiu P, Kim J, Poehlein C, de Bono JS.

J Clin Oncol. 2020 Feb 10;38(5):395-405. doi: 10.1200/JCO.19.01638. Epub 2019 Nov 27.

PMID:
31774688
7.

Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.

Gómez de Liaño Lista A, van Dijk N, de Velasco Oria de Rueda G, Necchi A, Lavaud P, Morales-Barrera R, Alonso Gordoa T, Maroto P, Ravaud A, Durán I, Szabados B, Castellano D, Giannatempo P, Loriot Y, Carles J, Anguera Palacios G, Lefort F, Raggi D, Gross Goupil M, Powles T, Van der Heijden MS.

Eur Urol. 2020 Feb;77(2):269-276. doi: 10.1016/j.eururo.2019.10.004. Epub 2019 Nov 5.

PMID:
31699525
8.

Erratum to 'Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma' [Eur J Cancer 108 (February 2019) 33-40].

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Sep;119:200-201. doi: 10.1016/j.ejca.2019.04.012. Epub 2019 Jul 11. No abstract available.

PMID:
31301937
9.

Which place for avelumab in the management of urothelial carcinoma?

Larroquette M, Gross-Goupil M, Daste A, Robert G, Ravaud A, Domblides C.

Expert Opin Biol Ther. 2019 Sep;19(9):863-870. doi: 10.1080/14712598.2019.1637412. Epub 2019 Jul 9.

PMID:
31286802
10.

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.

Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L.

J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13.

PMID:
31194611
11.

Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature.

de Vries-Brilland M, Sionneau B, Dutriaux C, Blay JY, Ravaud A, Gross-Goupil M.

Clin Genitourin Cancer. 2019 Aug;17(4):e721-e723. doi: 10.1016/j.clgc.2019.02.012. Epub 2019 Mar 15. No abstract available.

PMID:
31109800
12.

The interest of sequential treatment with immune check point inhibitors followed chemotherapy: A case report.

Lasserre M, Domblides C, Gross-Goupil M, Ravaud A, Daste A.

Oral Oncol. 2019 Jul;94:125-127. doi: 10.1016/j.oraloncology.2019.05.001. Epub 2019 May 8. No abstract available.

PMID:
31078371
13.

Asymptomatic stroke is an underestimated side effect of cabozantinib.

Bronnimann C, Sibon I, Ravaud A, Gross-Goupil M.

Rev Neurol (Paris). 2019 Jun;175(6):409-410. doi: 10.1016/j.neurol.2018.10.008. Epub 2019 May 2. No abstract available.

PMID:
31056194
14.

Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.

Auvray M, Auclin E, Barthelemy P, Bono P, Kellokumpu-Lehtinen P, Gross-Goupil M, De Velasco G, Powles T, Mouillet G, Vano YA, Gravis G, Mourey L, Priou F, Rolland F, Escudier B, Albiges L.

Eur J Cancer. 2019 Feb;108:33-40. doi: 10.1016/j.ejca.2018.11.031. Epub 2019 Jan 5. Erratum in: Eur J Cancer. 2019 Sep;119:200-201.

PMID:
30616146
15.

Traitement focal et traitement systémique dans la prise en charge du cancer du rein métastatique : une question de complémentarité.

Salabert L, Sionneau B, Cochin V, Ravaud A, Gross-Goupil M.

Bull Cancer. 2018 Dec;105 Suppl 3:S221-S228. doi: 10.1016/S0007-4551(18)30376-X. French.

PMID:
30595150
16.

Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial.

Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI.

Ann Oncol. 2018 Dec 1;29(12):2371-2378. doi: 10.1093/annonc/mdy454.

17.

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring.

Moeung S, Chevreau C, Poinsignon V, Guitton J, Lelièvre B, Ciccolini J, Gladieff L, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Delahousse J, Filleron T, Lochon I, Chatelut E, Thomas F.

Ther Drug Monit. 2019 Feb;41(1):66-74. doi: 10.1097/FTD.0000000000000569.

PMID:
30299429
18.

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.

Lebacle C, Bensalah K, Bernhard JC, Albiges L, Laguerre B, Gross-Goupil M, Baumert H, Lang H, Tricard T, Duclos B, Arnoux A, Piedvache C, Patard JJ, Escudier B.

BJU Int. 2019 May;123(5):804-810. doi: 10.1111/bju.14581. Epub 2018 Nov 20.

PMID:
30288884
19.

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.

Powles T, Motzer RJ, Escudier B, Pal S, Kollmannsberger C, Pikiel J, Gurney H, Rha SY, Park SH, Geertsen PF, Gross-Goupil M, Grande E, Suarez C, Markby DW, Arroyo A, Dean M, Choueiri TK, George D.

Br J Cancer. 2018 Sep;119(6):663-669. doi: 10.1038/s41416-018-0164-0. Epub 2018 Sep 10.

20.

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B.

N Engl J Med. 2018 Aug 2;379(5):417-427. doi: 10.1056/NEJMoa1803675. Epub 2018 Jun 3.

21.

Treatment of spinal metastases in renal cell carcinoma: A critical review.

Teyssonneau D, Gross-Goupil M, Domblides C, Haaser T, Pointillart V, Daste A, Hauger O, Ravaud A.

Crit Rev Oncol Hematol. 2018 May;125:19-29. doi: 10.1016/j.critrevonc.2018.02.017. Epub 2018 Mar 6. Review.

PMID:
29650272
22.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S.

Eur J Cancer. 2018 Jul;97:41-48. doi: 10.1016/j.ejca.2018.03.008. Epub 2018 Apr 7.

PMID:
29636272
23.

Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study.

Kostine M, Rouxel L, Barnetche T, Veillon R, Martin F, Dutriaux C, Dousset L, Pham-Ledard A, Prey S, Beylot-Barry M, Daste A, Gross-Goupil M, Lallier J, Ravaud A, Forcade E, Bannwarth B, Truchetet ME, Richez C, Mehsen N, Schaeverbeke T; FHU ACRONIM.

Ann Rheum Dis. 2018 Mar;77(3):393-398. doi: 10.1136/annrheumdis-2017-212257. Epub 2017 Nov 16.

PMID:
29146737
24.

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study.

Moeung S, Chevreau C, Broutin S, Guitton J, Lelièvre B, Ciccolini J, Massart C, Fléchon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Paci A, Marsili S, Malard L, Chatelut E, Thomas F.

Clin Cancer Res. 2017 Dec 1;23(23):7171-7179. doi: 10.1158/1078-0432.CCR-17-1344. Epub 2017 Sep 19.

25.

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators.

J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.

26.

[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].

Bertolaso P, Leroy L, Gross-Goupil M, Aupee O, Ravaud A, Roubaud G, Cazeau AL, Le Moulec S.

Bull Cancer. 2017 Sep;104(9):762-770. doi: 10.1016/j.bulcan.2017.06.011. Epub 2017 Aug 7. Review. French.

PMID:
28797482
27.

Immune checkpoint inhibitors and elderly people: A review.

Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V, de Mones E, Larmonier N, Soubeyran P, Ravaud A.

Eur J Cancer. 2017 Sep;82:155-166. doi: 10.1016/j.ejca.2017.05.044. Epub 2017 Jul 6. Review.

PMID:
28689093
28.

Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.

Daste A, Laine M, Gross-Goupil M, Bernhard JC, François L, Ravaud A.

Future Oncol. 2017 Jun;13(14):1219-1221. doi: 10.2217/fon-2017-0012. Epub 2017 Jun 13. No abstract available.

PMID:
28606002
29.

Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.

Noize P, Grelaud A, Bay JO, Chevreau C, Gross-Goupil M, Culine S, Ferrière JM, Moulin F, Robinson P, Balestra A, Lamarque S, Bernard MA, Lassalle R, Rouyer M, Droz-Perroteau C, Moore N, Fourrier-Réglat A, Ravaud A.

Pharmacoepidemiol Drug Saf. 2017 Dec;26(12):1561-1569. doi: 10.1002/pds.4228. Epub 2017 Jun 1.

PMID:
28573786
30.

Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature.

Bertolaso P, Gross-Goupil M, Molimard M, Cochin V, Ravaud A, Daste A.

Clin Genitourin Cancer. 2017 Oct;15(5):e885-e887. doi: 10.1016/j.clgc.2017.05.004. Epub 2017 May 10. Review. No abstract available.

PMID:
28552572
31.

Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.

Teyssonneau D, Daste A, Dousset V, Hoepffner JL, Ravaud A, Gross-Goupil M.

BMC Cancer. 2017 May 11;17(1):323. doi: 10.1186/s12885-017-3309-2.

32.

[Cabozantinib: Mechanism of action, efficacy and indications].

Cochin V, Gross-Goupil M, Ravaud A, Godbert Y, Le Moulec S.

Bull Cancer. 2017 May;104(5):393-401. doi: 10.1016/j.bulcan.2017.03.013. Epub 2017 May 3. French.

PMID:
28477875
33.

Posterior reversible encephalopathy syndrome with colitis in a patient treated with panitumumab.

Blaye C, Buy X, Gross-Goupil M, Vincent D, Jamet C, Sargos P, Culine S, Roubaud G.

Ther Adv Drug Saf. 2017 Apr;8(4):133-136. doi: 10.1177/2042098616682720. Epub 2017 Jan 16. No abstract available.

34.

How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma.

Bracarda S, Negrier S, Casper J, Porta C, Schmidinger M, Larkin J, Gross Goupil M, Escudier B.

Expert Rev Anticancer Ther. 2017 Mar;17(3):227-233. doi: 10.1080/14737140.2017.1276830. Epub 2017 Jan 3. Review.

PMID:
28044472
35.

Targeted therapy and elderly people: A review.

Daste A, Chakiba C, Domblides C, Gross-Goupil M, Quivy A, Ravaud A, Soubeyran P.

Eur J Cancer. 2016 Dec;69:199-215. doi: 10.1016/j.ejca.2016.10.005. Epub 2016 Nov 15. Review.

PMID:
27855351
36.

Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.

Oudard S, Joly F, Geoffrois L, Laguerre B, Houede N, Barthelemy P, Gross-Goupil M, Vano Y, Lucidarme O, Bidault F, Kelkouli N, Slimane K, Escudier B.

Clin Genitourin Cancer. 2016 Dec;14(6):e595-e607. doi: 10.1016/j.clgc.2016.04.019. Epub 2016 May 2.

PMID:
27283478
37.

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

Oudard S, Geoffrois L, Guillot A, Chevreau C, Deville JL, Falkowski S, Boyle H, Baciuchka M, Gimel P, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Denechere G, Amela EY, Abadie-Lacourtoisie S, Gross-Goupil M.

Eur J Cancer. 2016 Jul;62:28-35. doi: 10.1016/j.ejca.2016.04.003. Epub 2016 May 15.

PMID:
27192659
38.

Efficacy of Rechallenge of Metastatic Renal Cell Carcinoma Patient With Sunitinib After Prior Resistance to Axitinib: Case Report and Review of the Literature.

Daste A, Gross-Goupil M, Quivy A, François L, Bernhard JC, Ravaud A.

Clin Genitourin Cancer. 2016 Oct;14(5):e525-e527. doi: 10.1016/j.clgc.2016.04.009. Epub 2016 Apr 22. Review. No abstract available.

PMID:
27185091
39.

Prise en charge des tumeurs germinales du testicule en Aquitaine : état des lieux des pratiques en 2012.

Ferretti L, Gross-Goupil M, Sargos P, Cirilo Cassaigne I, Gaucher B, Demeaux H, Bousser V, Lebras Y, Pasticier G, Richaud P, Yacoub M, Roubaud G, Digue L.

Prog Urol. 2015 Nov;25(13):855. doi: 10.1016/j.purol.2015.08.280. French. No abstract available.

PMID:
26544475
40.

Sunitinib en rechallenge dans le cancer du rein métastatique-Résultats de l'étude RESUME.

Gimel P, Gross-Goupil M, Geoffrois L, Guillot A, Chevreau C, Deville J, Falkowski S, Boyle H, Baciuchka M, Laguerre B, Laramas M, Pfister C, Topart D, Rolland F, Legouffe E, Amela Y, Abadie S, Mahi N, Oudard S.

Prog Urol. 2014 Nov;24(13):821. doi: 10.1016/j.purol.2014.08.084. Epub 2014 Oct 30. French. No abstract available.

PMID:
26461610
41.

Enzalutamide and sleep apnea: an emerging central nervous system side-effect?

Labrize F, Cany L, Massard C, Loriot Y, Sargos P, Gross-Goupil M, Roubaud G.

Ann Oncol. 2016 Jan;27(1):206. doi: 10.1093/annonc/mdv481. Epub 2015 Oct 7. No abstract available.

42.

Dynamic contrast enhanced MRI-derived parameters are potential biomarkers of therapeutic response in bladder carcinoma.

Chakiba C, Cornelis F, Descat E, Gross-Goupil M, Sargos P, Roubaud G, Houédé N.

Eur J Radiol. 2015 Jun;84(6):1023-8. doi: 10.1016/j.ejrad.2015.02.026. Epub 2015 Mar 6.

PMID:
25796426
43.

Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma.

Elaidi R, Harbaoui A, Beuselinck B, Eymard JC, Bamias A, De Guillebon E, Porta C, Vano Y, Linassier C, Debruyne PR, Gross-Goupil M, Ravaud A, Aitelhaj M, Marret G, Oudard S.

Ann Oncol. 2015 Feb;26(2):378-85. doi: 10.1093/annonc/mdu552. Epub 2014 Dec 1.

44.

[Revision of therapeutic index for targeted treatment in kidney cancer: What if toxicity could predict efficacy?].

Grellety T, Brugères-Chakiba C, Chaminade A, Roubaud G, Ravaud A, Gross-Goupil M.

Bull Cancer. 2014 Jun;101(6):608-18. doi: 10.1684/bdc.2014.1935. Review. French.

PMID:
24977449
45.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
46.

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review.

Sargos P, Ferretti L, Gross-Goupil M, Orre M, Cornelis F, Henriques de Figueiredo B, Houédé N, Merino C, Roubaud G, Dallaudiére B, Richaud P, Fléchon A.

Prostate Cancer Prostatic Dis. 2014 Sep;17(3):220-6. doi: 10.1038/pcan.2014.17. Epub 2014 May 6. Review.

PMID:
24796290
47.

Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

Grellety T, Houédé N, Hoepffner JL, Rivière J, Mérino C, Lieutenant V, Gross-Goupil M, Richaud P, Dupin C, Sargos P, Roubaud G.

Ann Oncol. 2014 Jun;25(6):1248-9. doi: 10.1093/annonc/mdu132. Epub 2014 Apr 1. No abstract available.

48.

Pulmonary aspergilloma: an unexpected complication of radiofrequency ablation in the management of targeted therapy for a patient with metastatic renal cell carcinoma.

Daste A, Gross-Goupil M, Ravaud A.

Clin Genitourin Cancer. 2014 Jun;12(3):e115-6. doi: 10.1016/j.clgc.2014.01.003. Epub 2014 Jan 15. No abstract available.

PMID:
24524970
49.

Protein kinase inhibitors in renal cell carcinoma.

Daste A, Grellety T, Gross-Goupil M, Ravaud A.

Expert Opin Pharmacother. 2014 Feb;15(3):337-51. doi: 10.1517/14656566.2014.869210. Epub 2013 Dec 16. Review.

PMID:
24328606
50.

Emerging antiangiogenics for renal cancer.

Domblides C, Gross-Goupil M, Quivy A, Ravaud A.

Expert Opin Emerg Drugs. 2013 Dec;18(4):495-511. doi: 10.1517/14728214.2013.858697. Review.

PMID:
24274612

Supplemental Content

Loading ...
Support Center